Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DexComDXCM -1.24%94 3-1 Month Momentum % is 15.77% as of Jul. 22, 2026. GuruFocus rates DXCM with a GF Score™ of 94/100 and a GF Value™ of $104.58 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 844 Medical Devices & Instruments companies, DexCom ranks better than 89.81% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-22), DexCom's 3-1 Month Momentum % is 15.77%.
The industry rank for DexCom's 3-1 Month Momentum % or its related term are showing as below:
DXCM's 3-1 Month Momentum % is ranked better than 89.81% of 844
companies
in the Medical Devices & Instruments industry
Industry Median: -10.035
vs DXCM: 15.77
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
DexCom 3-1 Month Momentum % Related Terms
DXCM vs GEHC, STE, ZBH: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, DexCom's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexCom 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, DexCom's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where DexCom's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DexCom (DXCM) has a 3-1 Month Momentum % of 15.77% as of Jul. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on DexCom and its competitors. According to the industry distribution chart, DexCom ranks #86 out of 844 companies in the Medical Devices & Instruments industry, placing it in the top 10.2%.
Is DexCom's 3-1 Month Momentum % too high?
DexCom's current 3-1 Month Momentum % is 15.77%. Based on the distribution chart, DexCom ranks #86 out of 844 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, DexCom has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DexCom's 3-1 Month Momentum % compare to GEHC and STE?
According to the Medical Devices & Instruments industry distribution chart, DexCom ranks #86 out of 844 companies for 3-1 Month Momentum %. This places DexCom in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on DexCom and its competitors. DexCom's current 3-1 Month Momentum % is 15.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
Based on GuruFocus' analysis, DexCom (DXCM) is currently considered Modestly Undervalued. The stock's GF Value™ is $104.58, compared to a current price of $74.75 — trading 28.5% below its estimated fair value. The current 3-1 Month Momentum % is 15.77%. DexCom's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For DexCom (DXCM), the current 3-1 Month Momentum % is 15.77% as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DexCom (DXCM) Overvalued in 2026?
Based on GuruFocus' analysis, DexCom stock appears to be undervalued.
The current stock price of $74.75 is trading 28.5% below its estimated GF Value™ of $104.58.
GuruFocus considers DexCom to be Modestly Undervalued.
Key valuation signals for DXCM:
3-1 Month Momentum %: 15.77%
GF Value™: $104.58 vs. price of $74.75 (28.5% below fair value)
No single metric tells the full story. See the DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
94GF Score
Get the complete analysis for DXCM
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DXCM has been successfully added to your 
